Journal : Huanqiu Shibao website Date : Author : NA Page No. : NA
URL : NA

As at Beijing October 7, India’s new corona pneumonia confirmed cases crossed over 6.75 million cases. Some analysts believe that India has already exceeded the United States, because the actual number of infected people in the country may be more than 100 million people.

Photo:On September 28, in Gauhati, India, medical staff sampled a man for new coronavirus testing

I still remember that on September 26, local time, Indian Prime Minister Narendra Modi made a high profile promise on the epidemic at a video speech at the United Nations General Assembly . He said that India is the world’s largest vaccine manufacturer and that the “Indian vaccine” will help all mankind survive the epidemic once it comes out.

If that be the case, before helping all mankind, please ask India to help its people first.

So, is the Indian “magic medicine” really that powerful? The movie “I’m Not the God of Medicine” tells us: India has generic drugs, which are as effective as genuine drugs, but the price may be only 1/10 of the genuine ones, or even lower. Therefore, for most ordinary people suffering from severe illness, it is tantamount to opening a window of new life again.

The cost of developing a drug by international biomedical giants is very high. In case of those specific drugs used for treating cancer, it’s not that the drugs themselves are so expensive, but the additional R&D costs of developing specific drugs. For example, Novartis, which develops Gleevec, has an average research and development cost of US$4 billion for each new drug. Therefore, the unit price of Gleevec is as high as 11,500 yuan/box. If chronic myelogenous leukemia requires 2 boxes a month, it will cost 23,000. yuan. This is obviously not something ordinary people can afford.

So the question is, why can India ignore the copyright protection of international giants and unscrupulously imitate their products? That’s because all specific medicines require “human trials”, in addition to animals, to verify their therapeutic effects. India has a large population, a huge gap between the rich and the poor, and the development of infrastructure lags behind. The clinical trials of biological giants can give the volunteers subjecting themselves to trials an income, and naturally some people are willing to participate.

There are definite risks in such trials, and each country has different tolerance for these risks. If clinical trials are conducted in Europe and the United States, not only will the review be strict, but if they fail, the pharmaceutical giants will have to pay huge indemnities and their reputation will be damaged. Therefore, India has become the “ideal place” for the international biological giants.

Faced with a poverty-stricken society in India, the Indian Government can only cooperate with bio-giants, so that it can not only develop its own pharmaceutical industry and increase income through “flexible” methods (imitation), but ordinary people can also afford expensive drugs. Of course, the price paid in the process is that there will be casualties in the course of trials.

Therefore, the international biological giants turn a blind eye to reach such a “deal” with the Indian Government. After all, without the Indian “factories”, many trials would not be possible. And once trials have been conducted, India’s generic drugs are (certified) “just right”. Of course, these generic drugs are provided not only to the Indian people, but also “exported” to many developing countries and this has developed into an industry.

print
Share now